The Administrative Core will be responsible for managerial oversight of all Johns Hopkins Prostate CancerSPORE Program activities. In addition, the Core will help facilitate interactions between Johns HopkinsProstate Cancer SPORE Program Investigators and Investigators associated with other Prostate CancerSPORE Programs, and help orchestrate productive responses to the new National Cancer Instituteinitiatives. The managerial structure of the Johns Hopkins Prostate Cancer SPORE Program, with itsPrincipal Investigator, Co-Principal Investigator, Executive Committee, Internal Oversight Committee, andExternal Scientific Advisory Board, has been designed to promote translational research by creating aprostate cancer research culture and transcends academic Departments, medical disciplines, and individualresearch skills, and providing high quality monitoring, evaluation, and oversight of the SPORE portfolio ofResearch Projects, Core Resources, the Career Development Program, and the Developmental ResearchProgram. The Administrative Core will provide communications, resources, including teleconferencing,travel funds, and administrative staffing for all its managerial activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA058236-14
Application #
7468665
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Project Start
2008-04-01
Project End
2013-03-31
Budget Start
2008-04-01
Budget End
2009-08-31
Support Year
14
Fiscal Year
2008
Total Cost
$155,955
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Teply, Benjamin A; Wang, Hao; Luber, Brandon et al. (2018) Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol 19:76-86
Zennami, Kenji; Choi, Su Mi; Liao, Ross et al. (2018) PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance. Mol Cancer Res :
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Joshu, Corinne E; Peskoe, Sarah B; Heaphy, Christopher M et al. (2018) Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells. Prostate 78:233-238
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663
Shrestha, Eva; White, James R; Yu, Shu-Han et al. (2018) Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol 199:161-171
Lu, Yunqi; Hu, Zhongyi; Mangala, Lingegowda S et al. (2018) MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res 78:64-74
Das, Swadesh K; Pradhan, Anjan K; Bhoopathi, Praveen et al. (2018) The MDA-9/Syntenin/IGF1R/STAT3 Axis Directs Prostate Cancer Invasion. Cancer Res 78:2852-2863
Karnes, R Jeffrey; Choeurng, Voleak; Ross, Ashley E et al. (2018) Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol 73:168-175

Showing the most recent 10 out of 750 publications